2024-07-11 09:41:15
Medical artificial intelligence (AI) startup Beamworks (CEO Wonhwa Kim and Jaeil Kim) announced that it has begun a prospective clinical verification study of its real-time breast ultrasound AI diagnosis solution ‘CadAI-B’ in Hong Kong, following Taiwan.
This clinical trial aims to evaluate the usability and clinical efficacy of CadAI-B in a real-world clinical setting. This prospective clinical study, conducted at Tung Wah Hospital in Hong Kong, is led by Professor Ava Kwaang (鄺靄慧), a breast surgeon.
The aim of this prospective study is to apply CadAI-B to the medical field and prospectively confirm the actual clinical effectiveness. The research team plans to complete the study by May 2025 by targeting 50 female patients aged 20 years or older who visit Tung Wah Hospital in Hong Kong for breast screening.
Starting with this Hong Kong prospective clinical study, Beamworks plans to conduct a global multi-institutional prospective clinical trial recruiting 150 subjects with Kyungpook National University Hospital in Chilgok and Kazakhstan Astana University of Medical Sciences (AMU) and University Hospital (UMC) as joint research institutions.
Beamworks CEO Kim Won-hwa and Kim Jae-il said, “Beamworks aims to increase the probability of early detection of breast cancer through accurate ultrasound diagnosis, and ultimately improve the breast cancer survival rate and quality of life for patients. Prospectively verifying how effectively CadAI-B works in an actual clinical environment can bring about changes in the early detection and treatment of breast cancer.” They added, “We will continue to work to prove the usefulness of CadAI-B in various medical environments.”
Reporter Yong-Seok Choi, Donga.com [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-07-11 09:41:15